Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock crashed.

Reaching for that stick of deodorant might be second nature in your morning routine, but dermatologists are raising red flags about certain ingredients that could be causing more harm than good.

Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...

Chronic skin conditions typically aren’t curable, but they can be managed with medication and by paying close attention to your lifestyle. Learn more about symptoms, treatments, and ways to feel ...